Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SILOBullishCorporate Developmentsnews

Medium materiality6/10

Silo Pharma Advances SPC-15 IND-Enabling Program with Stability Milestone

Jun 23, 2026, 8:20 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive IND-enabling stability data can raise a valuation inflection for SILO, especially if it accelerates IND submission timing; however, ultimate upside hinges on Phase 1 data and broader funding outcomes seen in small-cap biotech histories (e.g., variability in IND-to-approval timelines).

AI summary

What happened, with direct paths to the underlying reporting

Positive stability data for SPC-15 support ongoing IND-enabling development and potential Phase 1 submission. Nine months real-time and six months accelerated stability meet CMC requirements, reinforcing manufacturing readiness under cGMP. With Columbia University collaboration, Silo targets an accelerated 505(b)(2) pathway for PTSD and anxiety treatments.

SPC-15 stability meets nine months real-time, six months accelerated specs.
IND-enabling chemistry/CMC data align with long-term testing for IND submission.
CEO emphasizes cGMP adherence and progress toward first-in-human Phase 1.
SPC-15 targets PTSD/anxiety via intranasal 5-HT4 receptor agonist; Columbia collaboration.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.